Sydney, Australia, 4 April 2024 – In alignment with World Autism Month, BlinkLab Limited (ASX:BB1) proudly announces its listing on the Australian Securities Exchange (ASX) today, 4 April 2024, at 12:00pm AEDT (9:00am AWST). Founded by visionary neuroscientists at Princeton University, BlinkLab has carved a niche in advancing mental healthcare through the development of smartphone-based AI-powered solutions for the early diagnosis of autism, ADHD, and other neurodevelopmental conditions.
This strategic listing coincides with a period of heightened awareness and advocacy for autism, amplifying the significance of BlinkLab’s mission. Leveraging the capital raised, the company aims to complete a crucial FDA Class II medical device registration study in autism, in collaboration with top US university hospitals.
BlinkLab’s Chairman, Brian Leedman, expressed his excitement about the company’s innovative impact, saying, "I believe BlinkLab is the next groundbreaking venture in digital healthcare. Our innovative approach leverages the power of smartphones, AI and machine learning to deliver autism screening tests specifically designed for children as young as 18 months old. This will aid healthcare providers to identify these children at a much younger age than presently available providing a pathway to effective treatment and better outcomes for the child and their families. This cutting-edge digital technology is poised to capture the imagination of major industry players, eager to embrace transformative solutions in healthcare."
BlinkLab’s proprietary testing platform utilises smartphones to deliver and analyze stimuli with unprecedented precision. This approach has yielded promising results in clinical trials, demonstrating a high degree of accuracy in diagnosing autism.
Henk-Jan Boele, BlinkLab’s Cofounder and CEO, remarked on the timing of the ASX listing, "Our ASX debut during World Autism Month is a poignant reminder of our dedication to bridging the gap between groundbreaking science and the real-world needs of families navigating neurodevelopmental challenges."
With plans to embark on a registrational study for FDA 510(k) registration and explore diagnostic solutions for additional conditions, BlinkLab envisions a future where AI-driven tools are integral to personalised, accurate mental healthcare.
About us:
BlinkLab Limited (ASX:BB1), a pioneer in the realm of AI-powered mental healthcare diagnostics, was founded on the innovative work of neuroscientists from Princeton University. Specializing in smartphone-based diagnostics, BlinkLab is committed to improving the early detection and treatment of neurodevelopmental disorders. Positioned at the intersection of technology and healthcare, BlinkLab strives to make a meaningful difference in the lives of individuals and families affected by these conditions.
Contact details:
Jane Morgan